Cholestyramine, a proposed cholesterol lowering drug, was administered to 164 men for an average of seven years each.
The response variable is a man's decrease in cholesterol
level over the course of the experiment.
The single predictor is compliance, the fraction of intended dose
actually taken (standardized)